Pipeline

We’re developing novel small molecule therapies targeting the most common genetic mutation affecting cystic fibrosis (CF) patients, ΔF508, with the goal of normalizing CFTR function. Our programs targeting the NBD1, ICL4, and TMD1 regions of CFTR are complementary, and together they have the potential to achieve best in class efficacy by normalizing CFTR function.